Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;40(8):3285-3297.
doi: 10.1007/s10067-021-05646-2. Epub 2021 Feb 17.

Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement

Affiliations

Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement

Bogdan Obrișcă et al. Clin Rheumatol. 2021 Aug.

Abstract

Introduction: We sought to investigate the infection profile and associated risk factors in a compiled cohort of patients with autoimmune disorders with severe renal involvement treated with aggressive immunosuppressive (IS) regimens.

Methods: A total of 162 patients with aggressive glomerulonephritis [101 with lupus nephritis (LN), 24 with cryoglobulinemic vasculitis (CryoVasc), and 37 with ANCA-associated vasculitis (AAV)] were retrospectively reviewed for any infection occurrence. Infection incidence, type, site, and grade (1-5) were recorded. Multivariate Cox proportional hazard regression analysis was performed to identify independent risk factors for infections.

Results: A total of 179 infection episodes occurred during a follow-up of 468 patient-years. Eighty-two patients (50.6%) had at least one infection. The incidence rates of infections and severe infections were 38.2 and 14.3 events per 100 patient-years. Patients with AAV had more infections than those with CryoVasc and LN (100.6, 47.5, and 26.6 infections per 100-patient-years, respectively; p = 0.002). Most patients developed infections early during the initial induction therapy (62.1% in the first 6 months of follow-up). In multivariate Cox regression analysis, high-dose oral corticosteroids (≥ 0.5 mg/kg/day in the first month of induction therapy) was an independent predictor of any infection (HR 2.66; 95% CI, 1.5-4.73), severe infections (HR 2.45; 95% CI, 1.03-5.82), and pulmonary infections (HR 2.91; 95% CI, 1.05-8.01). Pulmonary involvement increased the risk for pulmonary infections (HR 3.67; 95% CI, 1.32-10.1) and severe infections (HR 2.45; 95% CI, 1.01-5.92).

Conclusion: Infections occur frequently with current IS regimens in aggressive glomerulonephritis. Pulmonary involvement and high-dose corticosteroid regimen were the most significant risk factors for infections. Key Points • Infections occur frequently with current immunosuppressive regimens in autoimmune aggressive glomerulonephritis. • High-dose corticosteroids are the major contributors to the risk for serious infections.

Keywords: Corticosteroids; Glomerulonephritis. Immunosuppression; Induction therapy.

PubMed Disclaimer

References

    1. Parikh SV, Rovin BH (2016) Current and emerging therapies for lupus nephritis. J Am Soc Nephrol 27(10):2929–2939 - PubMed - PMC - DOI
    1. Kitching AR, Anders HJ, Basu N, Brouwer E, Gordon J, Jayne DR, Kullman J, Lyons PA, Merkel PA, Savage COS, Specks U, Kain R (2020) ANCA-associated vasculitis. Nat Rev Dis Prim 6:71 - PubMed - DOI
    1. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C et al (2010) Early mortality in systemic vasculitis : relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043 - PubMed - DOI
    1. Austin HA, Klippel JH, Balow JE, Riche NGH, Steinberg AD, Plotz PH et al (1986) Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619 - PubMed - DOI
    1. Boumpas DT, Austin HA, Vaugn EM, Klippel JH, Steinberg AD, Yarboro CH et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745 - PubMed - DOI

MeSH terms

Substances

LinkOut - more resources